<?xml version="1.0" encoding="UTF-8"?>
<p id="Par69">In patients with CSU unresponsive to 2nd generation H1-antihistamines and omalizumab, ongoing treatment with cyclosporine A should not be stopped during the COVID-19 pandemic.</p>
